Here’s What Hedge Funds Think About ABIOMED, Inc. (ABMD)

In This Article:

There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Jeff Ubben, George Soros and Carl Icahn think. Those hedge fund operators make billions of dollars each year by hiring the best and the brightest to do research on stocks, including small cap stocks that big brokerage houses simply don't cover. Because of Carl Icahn and other elite funds' exemplary historical records, we pay attention to their small cap picks. In this article, we use hedge fund filing data to analyze ABIOMED, Inc. (NASDAQ:ABMD).

Is ABIOMED, Inc. (NASDAQ:ABMD) an attractive investment today? The best stock pickers are getting more optimistic. The number of bullish hedge fund bets improved by 9 recently. Our calculations also showed that ABMD isn't among the 30 most popular stocks among hedge funds.

Hedge funds' reputation as shrewd investors has been tarnished in the last decade as their hedged returns couldn't keep up with the unhedged returns of the market indices. Our research has shown that hedge funds' small-cap stock picks managed to beat the market by double digits annually between 1999 and 2016, but the margin of outperformance has been declining in recent years. Nevertheless, we were still able to identify in advance a select group of hedge fund holdings that outperformed the market by 32 percentage points since May 2014 through March 12, 2019 (see the details here). We were also able to identify in advance a select group of hedge fund holdings that underperformed the market by 10 percentage points annually between 2006 and 2017. Interestingly the margin of underperformance of these stocks has been increasing in recent years. Investors who are long the market and short these stocks would have returned more than 27% annually between 2015 and 2017. We have been tracking and sharing the list of these stocks since February 2017 in our quarterly newsletter.

John Overdeck of Two Sigma
John Overdeck of Two Sigma

We're going to take a glance at the latest hedge fund action encompassing ABIOMED, Inc. (NASDAQ:ABMD).

How have hedgies been trading ABIOMED, Inc. (NASDAQ:ABMD)?

At Q4's end, a total of 31 of the hedge funds tracked by Insider Monkey were bullish on this stock, a change of 41% from the previous quarter. On the other hand, there were a total of 20 hedge funds with a bullish position in ABMD a year ago. So, let's check out which hedge funds were among the top holders of the stock and which hedge funds were making big moves.